Bendamustine/brentuximab vedotin
- PDF / 170,074 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 141 Views
1 S
Various toxicities: 5 case reports In retrospective multicentre study of 41 patients, who were treated between 01 January 2016 and 31 December 2018, 5 patients including 2 men and a woman aged 23–40 years* [not all ages and sexes stated] were described, who developed neutropenia, peripheral neuropathy, rash, CMV infection or herpes zoster infection following treatment with bendamustine and brentuximabvedotin as a bridge to autologous hematopoietic stem cell transplantation (AHSCT) in classical Hodgkin lymphoma. All five patients were diagnosed with classical Hodgkin lymphoma and received 2 cycles of salvage chemotherapy previously including doxorubicin [adriamycin], bleomycin, vinblastine, dacarbazine (ABVD) as frontline therapy. Thereafter, they had refractory or relapse of the classical Hodgkin lymphoma. Hence, they all started receiving IV brentuximab vedotin 1.8 mg/kg on day 1 and IV bendamustine 90 mg/m2 on days 1 and 2 of a 21 days cycle (BV+B combination) as a bridge to AHSCT in the Hodgkin lymphoma. Subsequently, they developed brentuximab vedotin and bendamustine treatment-related adverse effects including neutropenia (1 Patient), peripheral neuropathy (1 Patient), rash (1 Patient), CMV infection (1 Patient) and herpes zoster infection (1 Patient). Bendamustine was discontinued in the patient who developed neutropenia [durations of treatments to reactions onsets and outcomes not stated]. Subsequently, they underwent AHSCT with etoposide, carmustine, melphalan and cytarabine (BEAM) conditioning regimen. * Identifying patient details (age and sex) have been obtained through direct communication with the author. Pinczes LI, et al. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma. Annals of Hematology 99: 2385-2392, No. 10, Oct 2020. Available from: URL: http://doi.org/10.1007/ 803505206 s00277-020-04204-1
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
